-
-
-
-
-
-
-
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
Audentes Therapeutics (BOLD) to be Acquired by Astellas Pharma for $60/share
-
-
-
-
-
-
-
Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019
-
-
-
-
-
-
-
Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences — Renewed Outlook, K
-
-
-
-
-
-
-
Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
-
-
-
-
-
-
-
Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018
-
-
-
-
-
-
-
Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

